Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kairos Pharma, Ltd. ( (KAPA) ) has provided an announcement.
On October 7, 2025, Kairos Pharma announced its selection to present at the European Society for Medical Oncology Congress in Berlin, Germany. The presentation will showcase interim results from a Phase 2 trial evaluating the safety and efficacy of apalutamide and carotuximab in treating advanced, castration-resistant prostate cancer. This development highlights the potential of Kairos’s investigational drug, ENV105, in addressing resistance to hormone therapies in prostate cancer, a significant clinical challenge.
The most recent analyst rating on (KAPA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with high unmet medical needs. The company aims to improve the efficacy of existing standard of care treatments for challenging forms of cancer.
Average Trading Volume: 5,113,022
Technical Sentiment Signal: Strong Buy
Current Market Cap: $25.31M
See more insights into KAPA stock on TipRanks’ Stock Analysis page.